Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design

Madhukar H. Trivedi, Patrick J. McGrath, Maurizio Fava, Ramin V. Parsey, Benji T. Kurian, Mary L. Phillips, Maria A. Oquendo, Gerard Bruder, Diego Pizzagalli, Marisa Toups, Crystal Cooper, Phil Adams, Sarah Weyandt, David W. Morris, Bruce D. Grannemann, R. Todd Ogden, Randy Buckner, Melvin McInnis, Helena C. Kraemer, Eva PetkovaThomas J. Carmody, Myrna M. Weissman

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Remission rates for Major Depressive Disorder (MDD) are low and unpredictable for any given antidepressant. No biological or clinical marker has demonstrated sufficient ability to match individuals to efficacious treatment. Biosignatures developed from the systematic exploration of multiple biological markers, which optimize treatment selection for individuals (moderators) and provide early indication of ultimate treatment response (mediators) are needed. The rationale and design of a multi-site, placebo-controlled randomized clinical trial of sertraline examining moderators and mediators of treatment response is described. The target sample is 300 participants with early onset (≤30 years) recurrent MDD. Non-responders to an 8-week trial are switched double blind to either bupropion (for sertraline non-responders) or sertraline (for placebo non-responders) for an additional 8 weeks. Clinical moderators include anxious depression, early trauma, gender, melancholic and atypical depression, anger attacks, Axis II disorder, hypersomnia/fatigue, and chronicity of depression. Biological moderator and mediators include cerebral cortical thickness, task-based fMRI (reward and emotion conflict), resting connectivity, diffusion tensor imaging (DTI), arterial spin labeling (ASL), electroencephalograpy (EEG), cortical evoked potentials, and behavioral/cognitive tasks evaluated at baseline and week 1, except DTI, assessed only at baseline. The study is designed to standardize assessment of biomarkers across multiple sites as well as institute replicable quality control methods, and to use advanced data analytic methods to integrate these markers. A Differential Depression Treatment Response Index (DTRI) will be developed. The data, including biological samples (DNA, RNA, and plasma collected before and during treatment), will become available in a public scientific repository.Clinical Trial Registration: Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression (EMBARC).Identifier: NCT01407094.URL: http://clinicaltrials.gov/show/NCT01407094.

Original languageEnglish (US)
Pages (from-to)11-23
Number of pages13
JournalJournal of Psychiatric Research
Volume78
DOIs
StatePublished - Jul 1 2016

Fingerprint

Antidepressive Agents
Sertraline
Depression
Biomarkers
Diffusion Tensor Imaging
Major Depressive Disorder
Therapeutics
Placebos
Disorders of Excessive Somnolence
Bupropion
Aptitude
Anger
Reward
Evoked Potentials
Quality Control
Fatigue
Antidepressants
Emotions
Randomized Controlled Trials
Magnetic Resonance Imaging

Keywords

  • Antidepressant response
  • Biosignatures
  • EMBARC
  • Mediators
  • Moderators
  • Sertraline

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Arts and Humanities (miscellaneous)

Cite this

Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC) : Rationale and design. / Trivedi, Madhukar H.; McGrath, Patrick J.; Fava, Maurizio; Parsey, Ramin V.; Kurian, Benji T.; Phillips, Mary L.; Oquendo, Maria A.; Bruder, Gerard; Pizzagalli, Diego; Toups, Marisa; Cooper, Crystal; Adams, Phil; Weyandt, Sarah; Morris, David W.; Grannemann, Bruce D.; Ogden, R. Todd; Buckner, Randy; McInnis, Melvin; Kraemer, Helena C.; Petkova, Eva; Carmody, Thomas J.; Weissman, Myrna M.

In: Journal of Psychiatric Research, Vol. 78, 01.07.2016, p. 11-23.

Research output: Contribution to journalArticle

Trivedi, MH, McGrath, PJ, Fava, M, Parsey, RV, Kurian, BT, Phillips, ML, Oquendo, MA, Bruder, G, Pizzagalli, D, Toups, M, Cooper, C, Adams, P, Weyandt, S, Morris, DW, Grannemann, BD, Ogden, RT, Buckner, R, McInnis, M, Kraemer, HC, Petkova, E, Carmody, TJ & Weissman, MM 2016, 'Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design', Journal of Psychiatric Research, vol. 78, pp. 11-23. https://doi.org/10.1016/j.jpsychires.2016.03.001
Trivedi, Madhukar H. ; McGrath, Patrick J. ; Fava, Maurizio ; Parsey, Ramin V. ; Kurian, Benji T. ; Phillips, Mary L. ; Oquendo, Maria A. ; Bruder, Gerard ; Pizzagalli, Diego ; Toups, Marisa ; Cooper, Crystal ; Adams, Phil ; Weyandt, Sarah ; Morris, David W. ; Grannemann, Bruce D. ; Ogden, R. Todd ; Buckner, Randy ; McInnis, Melvin ; Kraemer, Helena C. ; Petkova, Eva ; Carmody, Thomas J. ; Weissman, Myrna M. / Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC) : Rationale and design. In: Journal of Psychiatric Research. 2016 ; Vol. 78. pp. 11-23.
@article{4104f647b2564590998021680d64e2c2,
title = "Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design",
abstract = "Remission rates for Major Depressive Disorder (MDD) are low and unpredictable for any given antidepressant. No biological or clinical marker has demonstrated sufficient ability to match individuals to efficacious treatment. Biosignatures developed from the systematic exploration of multiple biological markers, which optimize treatment selection for individuals (moderators) and provide early indication of ultimate treatment response (mediators) are needed. The rationale and design of a multi-site, placebo-controlled randomized clinical trial of sertraline examining moderators and mediators of treatment response is described. The target sample is 300 participants with early onset (≤30 years) recurrent MDD. Non-responders to an 8-week trial are switched double blind to either bupropion (for sertraline non-responders) or sertraline (for placebo non-responders) for an additional 8 weeks. Clinical moderators include anxious depression, early trauma, gender, melancholic and atypical depression, anger attacks, Axis II disorder, hypersomnia/fatigue, and chronicity of depression. Biological moderator and mediators include cerebral cortical thickness, task-based fMRI (reward and emotion conflict), resting connectivity, diffusion tensor imaging (DTI), arterial spin labeling (ASL), electroencephalograpy (EEG), cortical evoked potentials, and behavioral/cognitive tasks evaluated at baseline and week 1, except DTI, assessed only at baseline. The study is designed to standardize assessment of biomarkers across multiple sites as well as institute replicable quality control methods, and to use advanced data analytic methods to integrate these markers. A Differential Depression Treatment Response Index (DTRI) will be developed. The data, including biological samples (DNA, RNA, and plasma collected before and during treatment), will become available in a public scientific repository.Clinical Trial Registration: Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression (EMBARC).Identifier: NCT01407094.URL: http://clinicaltrials.gov/show/NCT01407094.",
keywords = "Antidepressant response, Biosignatures, EMBARC, Mediators, Moderators, Sertraline",
author = "Trivedi, {Madhukar H.} and McGrath, {Patrick J.} and Maurizio Fava and Parsey, {Ramin V.} and Kurian, {Benji T.} and Phillips, {Mary L.} and Oquendo, {Maria A.} and Gerard Bruder and Diego Pizzagalli and Marisa Toups and Crystal Cooper and Phil Adams and Sarah Weyandt and Morris, {David W.} and Grannemann, {Bruce D.} and Ogden, {R. Todd} and Randy Buckner and Melvin McInnis and Kraemer, {Helena C.} and Eva Petkova and Carmody, {Thomas J.} and Weissman, {Myrna M.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1016/j.jpsychires.2016.03.001",
language = "English (US)",
volume = "78",
pages = "11--23",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC)

T2 - Rationale and design

AU - Trivedi, Madhukar H.

AU - McGrath, Patrick J.

AU - Fava, Maurizio

AU - Parsey, Ramin V.

AU - Kurian, Benji T.

AU - Phillips, Mary L.

AU - Oquendo, Maria A.

AU - Bruder, Gerard

AU - Pizzagalli, Diego

AU - Toups, Marisa

AU - Cooper, Crystal

AU - Adams, Phil

AU - Weyandt, Sarah

AU - Morris, David W.

AU - Grannemann, Bruce D.

AU - Ogden, R. Todd

AU - Buckner, Randy

AU - McInnis, Melvin

AU - Kraemer, Helena C.

AU - Petkova, Eva

AU - Carmody, Thomas J.

AU - Weissman, Myrna M.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Remission rates for Major Depressive Disorder (MDD) are low and unpredictable for any given antidepressant. No biological or clinical marker has demonstrated sufficient ability to match individuals to efficacious treatment. Biosignatures developed from the systematic exploration of multiple biological markers, which optimize treatment selection for individuals (moderators) and provide early indication of ultimate treatment response (mediators) are needed. The rationale and design of a multi-site, placebo-controlled randomized clinical trial of sertraline examining moderators and mediators of treatment response is described. The target sample is 300 participants with early onset (≤30 years) recurrent MDD. Non-responders to an 8-week trial are switched double blind to either bupropion (for sertraline non-responders) or sertraline (for placebo non-responders) for an additional 8 weeks. Clinical moderators include anxious depression, early trauma, gender, melancholic and atypical depression, anger attacks, Axis II disorder, hypersomnia/fatigue, and chronicity of depression. Biological moderator and mediators include cerebral cortical thickness, task-based fMRI (reward and emotion conflict), resting connectivity, diffusion tensor imaging (DTI), arterial spin labeling (ASL), electroencephalograpy (EEG), cortical evoked potentials, and behavioral/cognitive tasks evaluated at baseline and week 1, except DTI, assessed only at baseline. The study is designed to standardize assessment of biomarkers across multiple sites as well as institute replicable quality control methods, and to use advanced data analytic methods to integrate these markers. A Differential Depression Treatment Response Index (DTRI) will be developed. The data, including biological samples (DNA, RNA, and plasma collected before and during treatment), will become available in a public scientific repository.Clinical Trial Registration: Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression (EMBARC).Identifier: NCT01407094.URL: http://clinicaltrials.gov/show/NCT01407094.

AB - Remission rates for Major Depressive Disorder (MDD) are low and unpredictable for any given antidepressant. No biological or clinical marker has demonstrated sufficient ability to match individuals to efficacious treatment. Biosignatures developed from the systematic exploration of multiple biological markers, which optimize treatment selection for individuals (moderators) and provide early indication of ultimate treatment response (mediators) are needed. The rationale and design of a multi-site, placebo-controlled randomized clinical trial of sertraline examining moderators and mediators of treatment response is described. The target sample is 300 participants with early onset (≤30 years) recurrent MDD. Non-responders to an 8-week trial are switched double blind to either bupropion (for sertraline non-responders) or sertraline (for placebo non-responders) for an additional 8 weeks. Clinical moderators include anxious depression, early trauma, gender, melancholic and atypical depression, anger attacks, Axis II disorder, hypersomnia/fatigue, and chronicity of depression. Biological moderator and mediators include cerebral cortical thickness, task-based fMRI (reward and emotion conflict), resting connectivity, diffusion tensor imaging (DTI), arterial spin labeling (ASL), electroencephalograpy (EEG), cortical evoked potentials, and behavioral/cognitive tasks evaluated at baseline and week 1, except DTI, assessed only at baseline. The study is designed to standardize assessment of biomarkers across multiple sites as well as institute replicable quality control methods, and to use advanced data analytic methods to integrate these markers. A Differential Depression Treatment Response Index (DTRI) will be developed. The data, including biological samples (DNA, RNA, and plasma collected before and during treatment), will become available in a public scientific repository.Clinical Trial Registration: Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression (EMBARC).Identifier: NCT01407094.URL: http://clinicaltrials.gov/show/NCT01407094.

KW - Antidepressant response

KW - Biosignatures

KW - EMBARC

KW - Mediators

KW - Moderators

KW - Sertraline

UR - http://www.scopus.com/inward/record.url?scp=84962220007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962220007&partnerID=8YFLogxK

U2 - 10.1016/j.jpsychires.2016.03.001

DO - 10.1016/j.jpsychires.2016.03.001

M3 - Article

C2 - 27038550

AN - SCOPUS:84962220007

VL - 78

SP - 11

EP - 23

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

SN - 0022-3956

ER -